Keywords: Lundbeck, Selincro, Biote, Nalmefene, Alcohol dependence, EMA, Novo Nordisk, Degludec, Diabetes, Japan

Lundbeck submits Selincro in EU; Novo Nordisk files Degludec in Japan

Article | 22 December 2011

Print This

Danish CNS drug specialist Lundbeck (LUND: DC) revealed yesterday that it has submitted a marketing authorization application to the European ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in